» Articles » PMID: 25154440

Ginsenoside Rh1 Induces Mouse Osteoblast Growth and Differentiation Through the Bone Morphogenetic Protein 2/runt-related Gene 2 Signalling Pathway

Overview
Specialties Pharmacology
Pharmacy
Date 2014 Aug 27
PMID 25154440
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: This study aimed to investigate the stimulative and pharmacological effects of ginsenoside Rh1 (hereinafter referred to as: Rh1) on differentiation and mineralization of osteoblast and its possible mechanism of action on the expression of bone morphogenetic protein 2 (BMP-2)/Runt-related gene 2 (Runx2) signalling pathways using mouse preosteoblastic MC3T3-E1 cell line as in-vitro model.

Methods: An in-vitro stimulative activity of Rh1 was assessed by analyzing alkaline phosphatase activity (ALP), type-I collagen (Coll-I) synthesis, mineralization and glutathione content. Its antioxidant activity was measured by evaluating the reactive oxygen species (ROS) production in the presence of antimycin A (AMA), one of the mitochondrial dysfunction factors. The level of BMP-2/Runx2 signal-regulated osteoblast-specific proteins such as osteocalcin (OCN), Coll-I and ALP were detected using Western blot analysis.

Key Findings: Rh1 was capable to stimulate cell growth, ALP activity, Coll-I synthesis, mineralization and glutathione content in the MC3T3-E1 cells. BMP-2 and Runx2 expression were also increased by Rh1 concentration dependently. Additionally, Rh1 also showed inhibitory action on the level of ROS production enhanced by AMA in MC3T3-E1 cells. Rh1 could increase the expression level of BMP-2/Runx2 signal-regulated osteogenic markers such as ALP, Coll-I and OCN.

Conclusions: Rh1, a protopanaxatriol type's active ingredients of Panax ginseng Meyer, possesses osteoblast differentiation, osteogenic stimulatory and anti-oxidative activity.

Citing Articles

Therapeutic Potential of Ginsenosides on Bone Metabolism: A Review of Osteoporosis, Periodontal Disease and Osteoarthritis.

Ko S Int J Mol Sci. 2024; 25(11).

PMID: 38892015 PMC: 11172997. DOI: 10.3390/ijms25115828.


Traditional Chinese Medicine Compound-Loaded Materials in Bone Regeneration.

Shi G, Yang C, Wang Q, Wang S, Wang G, Ao R Front Bioeng Biotechnol. 2022; 10:851561.

PMID: 35252158 PMC: 8894853. DOI: 10.3389/fbioe.2022.851561.


Emerging Natural-Product-Based Treatments for the Management of Osteoarthritis.

Perez-Lozano M, Cesaro A, Mazor M, Esteve E, Berteina-Raboin S, Best T Antioxidants (Basel). 2021; 10(2).

PMID: 33572126 PMC: 7914872. DOI: 10.3390/antiox10020265.


Treatment of tibial dyschondroplasia with traditional Chinese medicines: "Lesson and future directions".

Zhang H, Wang Y, Mehmood K, Chang Y, Tang Z, Li Y Poult Sci. 2020; 99(12):6422-6433.

PMID: 33248557 PMC: 7704743. DOI: 10.1016/j.psj.2020.08.055.


Effects of ginsenosides on bone remodelling for novel drug applications: a review.

Yang N, Liu D, Zhang X, Li J, Wang M, Xu T Chin Med. 2020; 15:42.

PMID: 32391072 PMC: 7201946. DOI: 10.1186/s13020-020-00323-z.